A Phase 1 interventional study of BMS-986553 in Systemic Lupus Erythematosus, Sjögren's Disease and Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Not yet recruiting at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 46th largest by planned enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 1, reaches primary completion later than 45 of the 49 other live ones, and was the 113th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
This study's planned enrollment of 60 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Browse Lupus Nephritis studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: BMS-986553
Specified dose on specified days
Number of participants with treatment emergent adverse events (TEAEs)
Time frame: Up to approximately 90 days post BMS-986553 infusion
Number of participants with serious adverse events (SAEs)
Time frame: Up to approximately 90 days post BMS-986553 infusion
Number of participants with adverse events of special interest (AESIs)
Time frame: Up to approximately 90 days post BMS-986553 infusion
Number of participants with clinically significant laboratory abnormalities
Time frame: Up to approximately 90 days post BMS-986553 infusion
Number of participants with dose limiting toxicities (DLTs) that occur in DLT evaluation period
Time frame: 28 days after first infusion of BMS-986553
Maximum observed blood concentration (Cmax) of BMS-986553
Time frame: Up to approximately week 96
Time of maximum observed blood concentration (Tmax) of BMS-986553
Time frame: Up to approximately week 96
Area under the curve (AUC) of BMS-986553
Time frame: Up to approximately week 96
Percentage of participants with interstitial lung disease (ILD) with no worsening of pulmonary function
Worsening is defined as decline of ≥ 10% in absolute forced vital capacity (FVC) from baseline.
Time frame: Up to approximately week 24
SLE participants: Percentage of participants achieving definition of remission in SLE (DORIS) remission
Time frame: Up to approximately week 24
SLE participants: Percentage of participants achieving lupus low disease activity state (LLDAS)
Time frame: Up to approximately week 24
SLE participants: Change from baseline in urine protein/creatinine ratio (UPCR)/proteinuria
Time frame: Up to approximately week 24
IIM participants: Proportion of participants achieving myositis response criteria total improvement score (MRC TIS) moderate or major response
Time frame: Up to approximately week 24
IIM participants: Change from baseline in International Myositis Assessment and Clinical Studies Group (IMACS) outcome measure set for disease activity
Time frame: Up to approximately week 24
IIM participants: Change from baseline in Cutaneous Dermatomyositis Disease Area & Severity Index (CDASI)
This will be assessed in dermatomyositis participants only within the IIM group.
Time frame: Up to approximately week 24
SSc participants: Proportion of participants achieving minimal clinically important difference (MCID) of 24% change from baseline of the Modified Rodnan Skin Score (mRSS)
Time frame: Up to approximately week 24
SSc participants: Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: Up to approximately week 24
SSc participants: Proportion of participants achieving Revised Composite Response Index in Systemic Sclerosis (CRISS) 25
Time frame: Up to approximately week 24
RA participants: Proportion of participants achieving low Disease Activity Score 28 (using CRP) (DAS28-CRP) from baseline
Time frame: Up to approximately week 24
RA participants: Change from baseline in HAQ-DI
Time frame: Up to approximately week 24
RA participants: Proportion of participants achieving Simple Disease Activity Index (SDAI) remission at week 24 from baseline
Time frame: Up to approximately week 24
SjD participants: Proportion of participants achieving Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) response
Time frame: Up to approximately week 24
SjD participants: Proportion of participants achieving Sjögren's Tool for Assessing Response (STAR) response
Time frame: Up to approximately week 24
SjD participants: Proportion of participants achieving EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) response of 3 or greater points
Time frame: Up to approximately week 24
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Start is estimated for Oct 2026; primary completion for Oct 2032, 71 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.